Ultragenyx Pharmaceutical

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

Company Growth (employees)
Type
Public
HQ
Novato, US
Founded
2010
Size (employees)
376 (est)
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
60 Leveroni Ct

Ultragenyx Pharmaceutical Data and Metrics

Ultragenyx Pharmaceutical Financial Metrics

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016
USD

Net income (Q1, 2017)

(68.3 m)

EBIT (Q1, 2017)

(70 m)

Market capitalization (17-Aug-2017)

2.5 b

Cash (31-Mar-2017)

159.5 m
Ultragenyx Pharmaceutical's current market capitalization is $2.5 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

133 k

R&D expense

46 m114.7 m183.2 m

General and administrative expense

10.8 m33 m64.9 m

Operating expense total

56.8 m147.7 m248.1 m

EBIT

(56.8 m)(147.7 m)(248 m)

EBIT margin, %

(186471%)

Interest income

608 k2.3 m3.8 m

Pre tax profit

(245.8 m)

Income tax expense

(35 k)

Net Income

(59.8 m)(145.6 m)(245.9 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

17 k111 k

R&D expense

17.4 m23.1 m29.7 m40.4 m43.3 m48.7 m51.3 m

General and administrative expense

4.1 m7 m10.2 m13.2 m14.7 m17.2 m18.7 m

Operating expense total

21.5 m30.1 m39.9 m53.6 m58.1 m65.9 m70 m

EBIT

(21.5 m)(30.1 m)(39.9 m)(53.6 m)(58.1 m)(65.8 m)(70 m)

EBIT margin, %

(341488%)(59264%)

Interest income

273 k456 k673 k984 k971 k922 k1.1 m

Net Income

(21.4 m)(29.8 m)(39.2 m)(52.8 m)(56.9 m)(64.9 m)(68.3 m)
USDFY, 2014FY, 2015FY, 2016

Cash

24.3 m93.6 m161.1 m

Inventories

5.9 m13.1 m20.1 m

Current Assets

193.4 m450.2 m401.7 m

PP&E

3 m7.4 m17.1 m

Total Assets

198 m559.6 m540.6 m

Accounts Payable

4.9 m2.9 m5.4 m

Current Liabilities

12.5 m27.9 m60.3 m

Total Liabilities

66.7 m

Additional Paid-in Capital

324.1 m816.6 m1 b

Retained Earnings

(139 m)(284.7 m)(530.5 m)

Total Equity

531.1 m474 m

Financial Leverage

1.1 x1.1 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

178 m52.4 m166.7 m70.8 m55.1 m142.3 m159.5 m

Current Assets

350.5 m336.5 m460.7 m430.2 m411.1 m416.8 m444.7 m

PP&E

3.5 m4.8 m6.3 m13.4 m17.1 m18.2 m16.5 m

Total Assets

355.8 m343 m602.1 m524.2 m482 m515.2 m545.8 m

Accounts Payable

5.8 m10.2 m4.4 m6 m7 m6.6 m8.3 m

Current Liabilities

14.2 m23 m24.7 m29.9 m32 m50.4 m51.8 m

Additional Paid-in Capital

501.6 m509.7 m806.2 m827.1 m837.9 m915.1 m1.1 b

Retained Earnings

(160.4 m)(190.2 m)(229.4 m)(337.4 m)(394.3 m)(459.2 m)(598.8 m)

Total Equity

319.3 m576.8 m489.8 m443.9 m455.9 m488.5 m

Financial Leverage

1.1 x1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(59.8 m)(145.6 m)(245.9 m)

Depreciation and Amortization

684 k1.4 m3.4 m

Inventories

(4.1 m)(7.1 m)(7.1 m)

Accounts Payable

3.2 m(2 m)2.5 m

Cash From Operating Activities

(44.6 m)(106 m)(161 m)

Purchases of PP&E

(2.1 m)(5 m)(10.2 m)

Cash From Investing Activities

(123.4 m)(292.4 m)89.9 m

Cash From Financing Activities

185 m467.6 m138.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(21.4 m)(29.8 m)(39.2 m)(52.8 m)(56.9 m)(64.9 m)(68.3 m)

Accounts Payable

3.6 m4.2 m5.8 m10.2 m4.4 m6 m7 m6.6 m8.3 m
Y, 2017

Financial Leverage

1.1 x

Ultragenyx Pharmaceutical Market Value History

Traffic Overview of Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Life and Culture

You may also be interested in